| Cancer victim helps prescribe spiritual Rx for patients at local ...
Right before Christmas, a woman sat quietly in a sterile medical office in Riverside, Calif. as she listened to the results of recent tests. Her Kaiser doctor explained the options she had—to live or die. Lynn Koch, who was diagnosed with breast cancer Dec. 6, had the biopsy two days later and before she got dressed they asked when she wanted to schedule surgery. "It all went so fast," she said. "But I had no fear." Since then she has been cleared of cancer and has started a yearlong treatment of chemotherapy to keep the cancer from recurring. She credits a prescription she was given from a man in Tennessee with the results of her quick healing and "fear-free" existence, knowing many women die as a result of this disease every year.
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by ...
BOSTON, Nov. 7 /PRNewswire/ -- Ferring Pharmaceuticals presented the results of a cost-utility study supporting the adoption of EUFLEXXA(TM) (1% sodium hyaluronate) intra-articular hyaluronic acid (HA) for the relief of pain in patients with osteoarthritis (OA) of the knee at the American College of Rheumatology's Annual Scientific Meeting in Boston, MA, November 6-11. Using data from a larger trial, the study demonstrated that an intra- articular treatment course of HA (EUFLEXXA(TM)) for knee OA, as compared with non-HA therapy, provides a cost-utility benefit that supports adopting this technology. The data also show that wider adoption of this technology would result in greater financial savings to the health care system. Osteoarthritis is one of the most common diseases seen in the rheumatologist's office, costing the health care system nearly $100 billion per year.
EntreMed Commences Phase 2 Study With MKC-1 In Pancreatic Cancer
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that it has commenced a multi-center Phase 2 clinical trial with MKC-1 in patients with advanced pancreatic cancer. The primary objectives of this study will be to determine the antitumor activity of orally-administered MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least one prior chemotherapy regimen. The study will also assess the safety, tolerability and overall median survival time of pancreatic cancer patients treated with MKC-1. Massachusetts General Hospital Cancer Center is the lead institution for the study and Eunice Kwak, M.D., Ph.D., Assistant in Medicine, Tucker Gosnell Center for Gastrointestinal Cancers, will serve as the principal investigator.
|
